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Cancer stem cells (CSC) seem to be resistant to conventional chemo- and radiation therapies 
when compared with non-CSCs. Conventional cytotoxic therapies initially shrink the bulk 
of a tumor, but fail to eradicate it, resulting in tumor recurrence. Treatment failure may in 
part be due to the resistance of CSCs to chemotherapy or radiotherapy (Baumann et al., 
2008; Eyler & Rich, 2008).  
Drug or radiation surviving cells (residual tumor cells following treatment) have been 
shown to contain a higher frequency of putative CSCs in a number of human malignancies. 
Bao et al. demonstrated that the population of cells enriched for glioma CSCs was 
dramatically increased by irradiation and that radioresistant gliomas showed an increased 
percentage of CD133 positive cells (Bao et al., 2006). Tsuchida et al showed that anti-cancer 
drug treatment increases the side-population fraction (considered CSCs) in cancer cell lines 
(Tsuchida et al., 2008).  
Over the past decades, preoperative chemoradiotherapy (CRT) has been established as one 
approach in the multimodal treatment of several types of gastrointestinal malignancies. In 
rectal cancer, preoperative CRT followed by surgery has improved sphincter preservation, 
local pelvic control and survival of patients with locally advanced rectal cancer (Bosset et al., 
2006; Guillem et al., 2005). However, disease recurrence (especially for distant metastases) 
remains the major cause of mortality in these patients (Collette et al., 2007; van den Brink et 
al., 2004). 
In rectal cancer, tumor regression grading (TRG) following CRT was determined by 
quantifying the proportion of residual cancer cells to the stroma of the entire tumor bed on 
formalin-fixed paraffin embedded (FFPE) specimens. TRG or pathologic response has been 
shown to predict clinical outcome (disease recurrence or patient survival) of oesophageal 
(Brücher et al., 2006; Chirieac et al., 2005), gastric (Patel et al., 2007; Rohatgi et al., 2006), or 
rectal cancer (Rödel et al., 2005) in patients after preoperative CRT followed by surgery, 
rather than pre-CRT clinical stage. The amount of residual cancer cells after CRT seems to be 
predictive of disease recurrence and survival in relation to CRT resistance.  
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Therefore, we hypothesized that CRT decreased or eradicated non-CSCs, which are sensitive 
to CRT, while increasing the percentage of putative CSCs characteristic of CRT resistance in 
the population of residual cancer cells. Residual cancer cells following CRT may be expected 
to contain a higher frequency of putative CSCs expressing stem cell markers, compared to 
primary, non-CRT tumor cells.  
To test this hypothesis, we investigated the expression of stem cell markers in post-CRT 
residual cancer cells on FFPE specimens using microdissection and real-time quantitative 
reverse transcription polymerase chain reaction (RT-PCR).  
2. Microdissection and RNA isolation from FFPE specimens 
2.1 Microdissection in FFPE specimens  
Tumor specimens were fixed in 10% formaldehyde solution v/v and embedded in paraffin. 
FFPE specimens (10 μm sections) were stained with nuclear fast red (Vector Laboratories, 
Inc., CA) and subsequently manually microdissected under microscope magnification (from 
×5 to ×10). Residual cancer cells were isolated using a sterile blade and carefully collected 
with reference to hematoxylin and eosin sections, containing more than 70% cancer cells. 
Fibrotic tissue areas, necrotic cells, and non-neoplastic cells were identified.  
2.2 RNA extraction from FFPE specimens 
Microdissected samples were digested with proteinase K in lysis buffer containing Tris-HCl, 
EDTA, and sodium dodecyl sulfate as previously reported with minor modification 
(Bijwaard et al., 2001). RNA was purified using phenol and chloroform extraction. Isolated 
RNA was purified using ethanol precipitation. The concentration and quality of RNA was 
measured with UV absorbance at 260 nm and 280 nm (A260/280 ratio).  
3. Expression of stem cell markers in residual cancer cells after CRT 
3.1 cDNA synthesis 
To reverse transcribe the fragmented mRNA from FFPE tissue materials, we used random 
hexamer priming, instead of oligo (dT)-based priming. cDNA was synthesized with random 
hexamer and Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA) according to 
the manufacturer’s instructions.  
3.2 Real-time quantitative RT-PCR 
Real-time quantitative RT-PCR analysis was performed using a fluorescence-based real-time 
detection method (TaqMan) and an ABI PRISM 7700 Sequence Detection System (Applied 
Biosystems, Inc., Foster City, CA). Although SYBR-Green based detection is less specific 
than TaqMan-based detection, we used SYBR-Green based detection to save experimental 
time and costs.  
Primers were strictly selected or designed to be intron spanning to avoid amplification from 
contaminated genomic DNA. Target sequences were kept as small as possible 
(approximately 100 bp) to ensure the detection of fragmented and partially degraded RNA. 
To confirm primer specificity, a single band of expected amplicon size for each target gene 
was verified using gel electrophoresis on a 2% agarose gel and visualized with ethidium 
bromide.  
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Primers for CD133, CD44, OCT4, SOX2, VEGF, and beta actin were designed with primer3 
software (Biology Workbench Version 3.2, San Diego Supercomputer Center, at the 
University of California, San Diego). Primers for EGFR were synthesized according to 
previously published sequences (Schneider et al., 2005). Primer sequences are shown in 
Table 1. PCR was performed in a final volume of 25 μl with a SYBR Green PCR Master Mix 
using 1 μl cDNA, and 400 nM of each primer for the respective genes. Cycling conditions 
were 50°C for 2 min and 95°C for 10 min followed by 40 cycles at 95°C for 15 s and 60°C for 
1 min.  
 
gene primer sequence product size 
CD133 Forward 5'-GCTTTGCAATCTCCCTGTTG-3'  
 Reverse 5'-TTGATCCGGGTTCTTACCTG-3' 94bp 
CD44 Forward 5'-CGGACACCATGGACAAGTTT-3'  
 Reverse 5'-CACGTGGAATACACCTGCAA-3' 115bp 
OCT-4 Forward 5'-CTGGAGAAGGAGAAGCTGGA-3'  
 Reverse 5'-CAAATTGCTCGAGTTCTTTCTG-3' 79bp 
SOX2 Forward 5'-CAAGATGCACAACTCGGAGA-3'  
 Reverse 5'-GCTTAGCCTCGTCGATGAAC-3' 95bp 
VEGF Forward 5'-CAGAAGGAGGAGGGCAGAA-3'  
 Reverse 5'-CTCGATTGGATGGCAGTAGC-3' 80bp 
EGFR Forward 5'-CCTATGTGCAGAGGAATTATGATCTTT-3'  
 Reverse 5'-CCACTGTGTTGAGGGCAATG-3' 88bp 
Beta actin Forward 5'-ACAGAGCCTCGCCTTTGC-3'  
 Reverse 5'-GCGGCGATATCATCATCC-3' 75bp 
Table 1. Primer sequences of target genes 
3.3 Relative mRNA levels of target genes  
The parameter Ct (threshold cycle) is defined as the fractional cycle number at which the 
fluorescence generated by cleavage of the probe passes a fixed threshold above baseline. The 
Ct is inversely proportional to the amount of cDNA, i.e., a higher Ct value means that more 
PCR cycles are required to reach a certain level of detection.  
Relative mRNA levels were determined by the standard curve method. Standard curves and 
line equations were generated using five-fold serially diluted solutions of cDNA from colon 
cancer cell line, Lovo. All standard curves were linear in the analyzed range with an 
acceptable correlation coefficient (R2). Target gene expression was calculated using the 
standard curve.  
Quantitative normalization of cDNA in each sample was performed using the expression of 
the beta actin gene as an internal control. Finally, mRNA levels of the target gene were 
presented as ratios between the genes of interest and the internal reference gene (beta actin). 
Real-time PCR assays were performed twice for each sample and mean values were used for 
calculations of mRNA levels.  
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4. Difference in gene expression profile of primary tumor and residual tumor 
following CRT 
4.1 Correlations of CD133, SOX2 and OCT4 mRNA levels in pre-CRT or post-CRT 
tumor cells 
A cell surface protein CD133, known as prominim-1, has been regarded as one of the most 
important markers of colorectal CSCs (O'Brien et al., 2007; Ricci-Vitiani et al., 2007). OCT4 
and SOX2 are essential transcription factors for normal pluripotent cell development and 
maintenance in embryonic stem (ES) cells, which are also known as reprogramming genes 
that induce an ES cell-like state in fibroblasts i.e., induced pluripotent stem (iPS) cells 
(Takahashi et al., 2007; Yamanaka, 2008).  
As shown in Fig.1-1, we examined how these ‘stem cell’ related genes were correlated in 
primary non-treated tumor cells and post-CRT residual tumor cells. A positive correlation 
between OCT4 and SOX2 was observed in pre-CRT endoscopic tumor specimens. There was 
no correlation between CD133 and OCT4 or SOX2 in pre-CRT specimens. In post-CRT 
residual cancer on FFPE specimens (Fig. 1-2), significant positive correlations among all 





   
 
Fig. 1-1 Correlation between CD133, SOX2 and OCT4 in pre-CRT tumor biopsy specimens 
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Fig. 1-2 Correlation between CD133, SOX2 and OCT4 in post-CRT residual cancer cells 
Strong co-expression of OCT4 and SOX2 in both pre-and post-CRT tumor cells may indicate 
that these two genes have an indistinguishable relationship associated with maintenance of 
pluripotency in stem cells.  
Also, residual cancer cells surviving CRT may enrich a population of putative CSCs 
expressing CD133, OCT4 and SOX2 because of the potential association between CSCs and 
treatment resistance.  
4.2 Correlations of CD133, VEGF and EGFR mRNA levels in pre-CRT or post-CRT 
tumor cells 
The vascular endothelial growth factor (VEGF) and epidermal growth factor receptor 
(EGFR) pathways are closely associated with each other, and share common downstream 
signaling, especially for tumor angiogenesis. Increased expression of VEGF or EGFR has 
been reported to be involved in tumor aggressiveness, metastasis, and poor prognosis in 
several types of malignancies (Galizia et al., 2004; Galizia et al., 2006). To date, anti-VEGF 
and anti-EGFR antibodies have become indispensible in the treatment of metastatic CRC 
(Chau & Cunningham, 2009). In other words, both VEGF and EGFR are important 
therapeutic targets in CRC.  
We then examined how CD133 correlated with these therapeutic targets for CRC in primary 
tumor and post-CRT residual tumor cells. There were significant positive correlations 
between CD133 and VEGF, between CD133 and EGFR or between VEGF and EGFR in pre-
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CRT tumor biopsy specimens (Fig. 2-1). However, these correlations were not observed in 
post-CRT FFPE specimens (Fig. 2-2; Yasuda et al., 2009).  
We previously described several possibilities for explaining these findings. We believe it 
seems plausible that CRT may cause an imbalance between two distinct populations 
(putative CSCs and non-CSCs) within the tumor. A majority of tumor cells expressing VEGF 
and EGFR (considered as non-CSCs) may respond to CRT and then shrink or disappear. By 
contrast, a very small population of tumor cells expressing CD133 (considered as CSCs) may 
resist CRT and be left as residual cancer cells in post-CRT specimens.  
4.3 CD133 and CD44 expression in pre-CRT or post-CRT tumor cells 
CD44 is a transmembrane glycoprotein molecule, which is widely expressed as a cell surface 
hyaluronan receptor in normal epithelial, mesenchymal and hematopoietic cells. Also, CD44 
has been reported as one of the important cell surface markers for isolating colorectal CSCs 
(Du et al., 2008; Haraguchi et al., 2008).  
We examined whether the expression of potential markers (CD133 and CD44) for colorectal 
CSCs were changed during CRT. As shown in Fig. 3, tumoral CD133 mRNA levels were 
significantly increased in post-CRT resected specimens, compared with pre-CRT biopsy 
specimens. By contrast, tumoral CD44 mRNA levels were significantly decreased in residual 




           
Fig. 2-1 Correlation between CD133, VEGF and EGFR in pre-CRT tumor biopsy specimens 
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Fig. 2-2 Correlation between CD133, VEGF and EGFR in post-CRT residual cancer cells 
 
 
Fig. 3. CD133 and CD44 expression in paired pre-and post-CRT specimens 
The comparison of potential surface markers for colorectal CSCs between pre-CRT and post-
CRT tumor cells indicate that changes in expression of CD133 and CD44 during CRT were 
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quite opposite. We speculate that residual cancer following CRT may contain more CSCs 
than primary tumors before CRT. The relative proportion of CSCs may increase in residual 
cancer following CRT. Thus, gene expression related to CSCs may also increase in residual 
cancer following CRT, compared with primary tumors. In this context, CD133 seemed 
preferable to CD44 as the marker for colorectal CSCs.  
5. Radiation surviving cells in vitro and residual cancer cells after CRT 
5.1 CD133 and CD44 in radiation surviving HT-29 cells in vitro 
We performed an in vitro experiment using human colorectal cancer cell lines to determine 
whether irradiation itself can induce the expression of CD133 or CD44.  
Exponentially growing colorectal cells of the HT29 cell line were plated on a 10 cm dish and 
irradiated at a dose of 1, 2.5, and 5 Gy (CAX-150-20, Chubu medical Co. Ltd). Fourteen days 
later, colony formation assays were performed to evaluate cell survival after irradiation. 
Approximately 23%, 7%, and 5% survival fraction were found following irradiation with 1.0, 
2.5, and 5.0 Gy, respectively. These surviving cells were collected for western blotting 
analysis. Single dose of 2.5 Gy and 5 Gy radiation increased CD133 protein levels, compared 
with control (Fig. 4-1). Densitometric analysis showed that CD133 was 1.4 times increased at 
5 Gy radiation with respect to control. By contrast, radiation decreased CD44 protein levels 
regardless of radiation dose. 
 
 
Fig. 4-1 CD133 and CD44 in radiation surviving HT-29 cells in vitro 
CD133 increased in a radiation-dose dependent manner, despite the decreased number of 
radiation-surviving HT-29 cells. These in vitro results were consistent with CD133 mRNA 
levels increasing in residual cancer cells after CRT, compared with primary tumor cells 
before CRT. These results suggest that CRT may enrich the relative proportion of CD133 
expressing CSCs within residual cancer, or that CRT may induce the expression of CD133 in 
tumor cells, or both.  
5.2 Immunoreactive CD133 and CD44 in residual cancer cells after CRT 
For immunohistochemical analysis, CD133 rabbit monoclonal antibody (Cell Signaling 
Technology, Inc. Boston, MA) and CD44 mouse monoclonal antibody (R&D Systems, Inc. 
Minneapolis, MN) were used. The primary antibody was detected using Envision reagents 
(Envision kit/HRP, Dako Cytomation, Denmark).  
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Immunoreactive CD133 and CD44 expression were observed in the minority of residual 
cancer cells within entire residual tumors (Fig. 4-2). There was no obvious concordance 
between CD133 and CD44 positivity of residual cancer cells, which may support the notion 
that CD133 positive and CD44 positive cells did not colocalize in colorectal cancer 
specimens (Du et al., 2008).  
 
 
Fig. 4-2 Immunoreactive CD133 and CD44 in residual cancer cells after CRT 
CD133 immunostaining in residual cancer cells after CRT showed not only 
apical/endoluminal membranous staining, but also cytoplasmic staining. Immervoll et al 
reported that apical/endoluminal membranous CD133 staining was characteristic by well-
oriented, polarized and differentiated cells, while cytoplasmic CD133 staining was found in 
a minor population of cells (Immervoll et al., 2008). We have previously reported that 
residual cancer cells after CRT showed strong CD133 and moderate OCT4 and SOX2 
staining, but no CK20 staining (a known epithelial marker) was observed (Saigusa et al., 
2009). These lines of evidence suggest that CRT may induce dedifferentiation of cancer cells 
or may select putative CSCs with undifferentiated phenotype.  
To determine if CRT may increase the relative proportion of CD133 expressing CSCs within 
residual cancer, it is necessary to compare the number of CD133 expressing tumor cells in 
pre-CRT endoscopic biopsy specimens and post-CRT resected specimens. This study has not 
yet been completed.  
6. Clinical significance of CD133, OCT4, and SOX2 expression on residual 
cancer cells in patients with rectal cancer 
6.1 Association of post-CRT CD133, CD44, OCT4, and SOX2 expression with 
clinicopathological variables 
Thirty-three patients undergoing CRT followed by surgery were analyzed for an association 
between post-CRT OCT4 and SOX2 expression with clinical outcome. A total of 52 patients 
were analyzed for an association of post-CRT CD133 and CD44 expression with clinical 
outcome.  
Patients who developed distant metastatic recurrence (e.g. liver, lung) had a significantly 
higher post-CRT CD133, OCT4, and SOX2 compared with those patients without recurrence. 
No such relationship was observed for post-CRT CD44.  
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6.2 Association of post-CRT CD133, CD44, OCT4, and SOX2 expression with patient 
survival 
To identify the cut-off values of CD133, CD44, OCT4, and SOX2 predictive of distant 
metastatic recurrence, receiver operating curve (ROC) analysis was used. As shown in Fig. 
5, patients with post-CRT CD133, OCT4, and SOX2 above cut-off value (‘High’) showed 
significantly worse disease free survival, compared with those with ‘Low’. No such 




Fig. 5. Kaplan-Meier plots of disease free survival according to post-CRT CD133, CD44, 
SOX2, and OXT4 expression 
Introduction of preoperative CRT followed by surgery (total mesorectal excision) in the 
management of rectal cancer significantly decreased local recurrence rate and improved 
patients’ survival. However, the rate of distant metastatic recurrence still remains as high as 
15-20% of rectal cancer treated with preoperative CRT followed by TME (Guillem et al., 
2005). Identifying predictive markers for disease recurrence or poor prognosis of such 
patients is urgently required for appropriate treatment stratification.  
Our results suggest that the expression of ‘stem cell’ genes such as CD133, OCT4 and SOX2 
on post-CRT residual cancer cells may predict metachronous distant metastasis and poor 
prognosis of rectal cancer patients treated with preoperative CRT followed by surgery.  
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7. Clinical significance of residual cancer cells after CRT as putative 
colorectal CSCs 
7.1 The proportion of putative CSCs in primary tumors 
The presence of CSCs in primary tumors seems to be of prognostic significance for several 
malignancies (Liu et al., 2007; Zeppernick et al., 2008). In primary colorectal cancer, CD133 
expression has also been reported to be a significant prognostic marker (Horst et al., 2008; 
Kojima et al., 2008). This may indicate that the proportion of CD133 expressing CSCs in 
primary, non-treatment tumor might be predictive for less treatment efficacy, more chance 
of disease recurrence, and poor prognosis of CRC patients.  
In this study, the expression of CD133, CD44 SOX2, and OCT4 in pre-CRT primary tumor 
did not correlate with disease recurrence or survival of rectal cancer patients (data not 
shown). Since we had only 30 pre-CRT endoscopic tumor biopsies available, our data 
should be interpreted with caution. However, post-CRT, but not pre-CRT CD133, SOX2, and 
OCT4 has shown to be associated with metachronous distant metastasis and poor prognosis 
of rectal cancer patients treated with preoperative CRT followed by surgery.  
7.2 The proportion of putative CSCs in post-treatment residual tumors 
According to the CSC hypothesis, CRT surviving cancer cells (residual cancer cells following 
CRT) should contain a higher frequency of CRT-resistant colorectal CSCs, compared with 
primary, pre-CRT cancer cells. Our correlation results between pre-CRT or post-CRT CD133, 
SOX2, OCT4, VEGF, and EGFR, show that CRT may eliminate a majority of cancer cells 
expressing VEGF or EGFR (considered non-CSCs with CRT sensitive phenotype), and may 
leave a small population of cancer cells expressing CD133, OCT4, or SOX2 (considered CSCs 
with CRT resistant phenotype).  
Although we think that residual cancer cells are not completely identical to CSCs, our 
results suggest that the relative proportion of putative CSCs expressing CD133, OCT4, or 
SOX2 may increase in post-CRT residual cancer cells in FFPE specimens, compared with 
pre-CRT primary tumor cells. Our findings are consistent with recent experiments (Dallas et 
al., 2009; Dylla et al., 2008).  
7.3 CD133 and CD44 as potential markers for colorectal CSCs 
Both CD133 and CD44 are of functional importance as potential cell surface markers for 
colorectal CSC. It still remains to be resolved if either CD133 or CD44 could be clinically 
important in CRT surviving cells, or if CRT can increase the expression of these markers. In 
pre- and post-CRT paired specimens, significant increase in tumoral CD133 and significant 
decrease in tumoral CD44 was observed. In vitro, CD133, but not CD44 was increased in 
radiation-resistant surviving colorectal cancer cell lines (HT29 cells).  
CD133 seemed preferable to CD44 as the marker of colorectal CSCs according to the notion 
that CRT may increase the relative proportion of CSCs which express the potential markers 
of colorectal CSCs. 
8. Conclusion 
The proportion of CSCs in residual tumors following preoperative CRT may be more 
accurately predictive for less treatment efficacy, more chance of disease recurrence, and 
poor prognosis of rectal cancer patients than the proportion of CSCs in non-pretreatment 
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primary tumor. Expression of the potential markers of colorectal CSCs in microdissected 
residual cancer on FFPE specimens may provide useful information regarding treatment 
stratification and clinical management of rectal cancer patients after CRT and surgery.  
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